clinical trial · NCT01065454
A Study to Test the Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Left Ventricular Systolic Dysfunction
Bayer·phase2·completed·n = 202
Hypertension, PulmonaryVentricular Dysfunction, LeftRiociguat (Adempas, BAY63-2521)Riociguat (Adempas, BAY63-2521)Riociguat (Adempas, BAY63-2521)Placebo
brief summary
The aim of this study is to assess whether increasing oral doses of Riociguat are safe and improve the well-being, symptoms and outcome in patients with pulmonary hypertension associated with left ventricular systolic dysfunction
started
Apr 14, 2010
primary completion
Jun 6, 2012
completion
Jul 23, 2025
last updated
Aug 28, 2025
detailed description
Pharmacokinetics parameters were regarded as exploratory parameters. Adverse event data will be covered in Adverse events section.
official title
Randomized, Double Blind, Placebo Controlled, Parallel Group, Multi-center Study to Evaluate the Hemodynamic Effects of Riociguat (BAY 63-2521) as Well as Safety and Kinetics in Patients With Pulmonary Hypertension Associated With Left Ventricular Systolic Dysfunction
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol